Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira

Executive Summary

Adalimumab-atto is approved for seven indications on the reference product label but lacks four others that are protected by orphan product exclusivity; launch timing is unclear due 'patent dance' litigation.

Advertisement

Related Content

US Approvals Roundup: Cyltezo Biosimilar, Victoza CV Benefit, Gocovri In PD, Kedrab Rabies Biologic, Gout Combo Duzallo
Amgen's Avastin Biosimilar May Revive Orphan Indication Concerns
Drug Promotion: Exclusivity Warrants Narrow Exception From Free Speech Protections
How To Name A Biosimilar: Amgen Persisted With Amjevita Suffix Despite FDA Doubts
Biosimilars: Postmarketing Data Alone Not Enough For Interchangeability
FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi
Lobbying FDA: AbbVie Questions Humira Biosimilars In Private Meeting
AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
Inflectra Label Not Exactly Silent On Remicade's Orphan-Protected Claim

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119197

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel